email@example.com | 01484 472783
Dr Henry Chrystyn is the Professor and Head of Pharmacy at the University of Huddersfield, Huddersfield, West Yorkshire, UK. He was appointed to this new post in September 2007 and has the responsibility of introducing a new MPharm course (commenced in September 2008). Previously he was the Professor of Clinical Pharmacy in the School of Pharmacy at the University of Bradford.
He graduated with a BPharm from the University of Bradford in 1972 and became a registered pharmacist (MRPharmS) with the Royal Pharmaceutical Society of Great Britain in 1973. From 1973 he was employed as a hospital pharmacist and graduated with a MSc in Clinical Pharmacy in 1984 and then a PhD in 1987. In 1988 he joined the School of Pharmacy at the University of Bradford as a Lecturer in Pharmaceutical Technology and was appointed the Professor of Clinical Pharmacy in 1993. He is an Executive Editor of the British Journal of Clinical Pharmacology and was made a fellow (FRPharmS) of the Royal Pharmaceutical Society of Great Britain in 2007 for his contribution to research and the practice of pharmacy.
From 1988 he has published over 100 full papers and has supervised 34 PhD students with a further 4 still supervised at the University of Bradford and 3 newly registered PhD candidates at the University of Huddersfield. He has made several invited lectures within the pharmaceutical industry, at conferences and at academic institutions. He has presented over 60 international lectures and in excess of 250 national presentations. In 2008 he gave 8 international presentations. His research groups investigate the delivery of pharmaceutical care in hospital and community pharmacy as well as a group that investigates all aspects of inhaled therapies. The latter area of research is internationally recognised and includes in-vitro, ex-vivo and in-vivo studies. These studies involve the use of urinary pharmacokinetics methods to identify relative lung and systemic bioavailability after an inhalation (this has recently been extended to inhaled corticosteroids), in-vitro assessment of the emitted dose using conditions that simulate patient use, how patients use inhalers with emphasis on technique and inhalation profiles and medicines management of patients using inhalers.
At present he is a member of the ERS / ISAM Task Force involved with drawing up an ERS Consensus Statement on the use of inhalers. Also he is a member of the inhaler devices section of the BTS / SIGN Guidelines on the Management of Asthma.
On going studies involve the integration of laboratory compendial methodologies to identify the characteristics of the dose emitted from an inhaled products by using standard square valve vacuum pump technology (in-vitro) and by replaying patient inhalation profiles (ex-vivo techniques). Separate ex-vivo methodologies have been pioneered for metered dose inhalers, dry powder inhalers and nebulisers. Studies extend to the clinical environment with a focus on how patients use their inhalers (both at the national and the international level). These studies include an assessment of their disease control and characterisation of the inhalation profiles of patients when they use different inhalers. The impact of inhaler technique training is also investigated and other studies involve the identification of tools to help patients to use the correct inhalation technique for each type of inhaler.
Further studies include an assessment of the relative lung and systemic bioavailability of inhaled products and inhalation methods using urinary pharmacokinetic methods pioneered in our laboratory. A method for beclomethasone dipropionate has recently been developed and validated. Local collaboration exists with various clinical respiratory departments and physicians at the local level, nationally and internationally.
Investigations to evaluate the overall effectiveness of clinical pharmacy in the primary and secondary healthcare sectors with emphasis to medicine management. Areas of interest include therapeutic drug monitoring, pharmaceutical interventions, domiciliary visiting and the evaluation of prescribing data. Studies in asthma, COPD, Type 2 Diabetes, hypertension and lipid management have been carried out in the past.
Abdelrahim, M., Assi, K. and Chrystyn, H. (2013) ‘Dose emission and aerodynamic characterization of the terbutaline sulphate dose emitted from a Turbuhaler at low inhalation flow’ Pharmaceutical Development and Technology , 18 (4), pp. 944-949. ISSN 1083-7450
Chrystyn, H (2013) ‘Patients with asthma need to be able to use their inhaler effectively’ Guidelines in practice , 16 (4).
Ammari, W. and Chrystyn, H. (2013) ‘Optimizing the Inhalation Flow and Technique Through Metered Dose Inhalers of Asthmatic Adults and Children Attending a Community Pharmacy’ Journal of Asthma , pp. 1-9. ISSN 0277-0903
Price, D., Chrystyn, H., Corrigan, C., Rana, S., South, G. and Thomas, M. (2013) ‘The primary care management of asthma in real-life settings’ Guidelines in practice , 49 (1-5).
Price, D., Bosnic-Anticevich, S., Briggs, A., Chrystyn, H., Rand, C., Scheuch, G. and Bousquet, J. (2013) ‘Inhaler competence in asthma: Common errors, barriers to use and recommended solutions’ Respiratory Medicine , 107 (1), pp. 37-46. ISSN 0954-6111
Azouz, W., Campbell, J., Stephenson, J., Saralaya, D. and Chrystyn, H. (2013) ‘Improved metered dose inhaler technique when a co-ordination cap is used’ Journal of Aerosol Medicine and Pulmonary Drug Delivery . ISSN 1941-2711
Price, D., Bosnic-Anticevich, S., Briggs, A., Chrystyn, H., Rand, C., Scheuch, G. and Bousquet, J. (2012) ‘Inhaler competence in asthma: Common errors, barriers to use and recommended solutions’ Respiratory Medicine . ISSN 0954-6111
Britland, S., Finter, W., Chrystyn, H., Eagland, D. and Abdelrahim, M. (2012) ‘Droplet aerodynamics, cellular uptake and efficacy of a nebulizable corticosteroid nanosuspension are superior to a micronized dosage form’ Biotechnology Progress , 28 (5), pp. 1152-1159. ISSN 8756-7938
Ahmed, A., Harding, L. and Chrystyn, H. (2012) ‘Urinary pharmacokinetic methodology to determine the relative lung availability of inhaled beclometasone’ British Journal of Clinical Pharmacology , 74 (3), pp. 456-464. ISSN 1365-2125
Price, D., Chrystyn, H., van der Molen, T., Kaplan, A., Haughney, J., Román-Rodríguez, M., Burden, A., Chisholm, A., Hillyer, E., von Ziegenweidt, J. and Ali, M. (2012) ‘Effectiveness of Same Versus Mixed Asthma Inhaler Devices: A Retrospective Observational Study in Primary Care ’ Allergy Asthma and Immunology Research , 4 (4), pp. 184-191. ISSN 2092-7355
Azouz, W. and Chrystyn, H. (2012) ‘Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice’ Primary Care Respiratory Journal , 21 (2), pp. 208-213. ISSN 1471-4418
Chrystyn, H. and Niederlaender, C. (2012) ‘The Genuair® inhaler: a novel, multidose dry powder inhaler’ International Journal of Clinical Practice , 66 (3), pp. 309-317. ISSN 1368-5031
Chrystyn, H. and Haathala, T. (2012) ‘Real-life inhalation therapy inhaler performance and patient education matter’ European Respiratory Disease , 8 (1), pp. 11-18. ISSN 1754-5552
Abdelrahim, M., Plant, P. and Chrystyn, H. (2011) ‘The relative lung and systemic bioavailability of terbutaline following nebulisation in non-invasively ventilated patients’ International Journal of Pharmaceutics , 420 (2), pp. 313-318. ISSN 0378-5173
Müller, V., Gálffy, G., Eszes, N., Losonczy, G., Bizzi, A., Nicolini, G., Chrystyn, H. and Tamási, L. (2011) ‘Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation’ BMC Pulmonary Medicine , 11 (1), p. 40. ISSN 1471-2466
Azouz, W., Campbell, J. and Chrystyn, H. (2011) ‘Training tools for inhalation devices: the need for more sophistication ’ Primary Care Respiratory Journal , 20 (2), p. 221. ISSN 1471-4418
Laube, B., Janssens, H., Chrystyn, H., de Jongh, F., Devadason, S., Dhand, R., Diot, P., Everard, M., Horvath, I., Navalesi, P. and Voshaar, T. (2011) ‘What the pulmonary specialist should know about the new inhalation therapies’ European Respiratory Journal , 37 (6), pp. 1308-1417. ISSN 0903-1936
Abdelrahim, M., Assi, K. and Chrystyn, H. (2011) ‘Relative bioavailability of terbutaline to the lung following inhalation, using urinary excretion’ British Journal of Clinical Pharmacology , 71 (4), pp. 608-610. ISSN 1365-2125
De Matas, M., Shao, Q., Biddiscombe, M., Meah, S., Chrystyn, H. and Usmani, O. (2010) ‘Predicting the clinical effect of a short acting bronchodilator in individual patients using artificial neural networks’ European Journal of Pharmaceutical Sciences , 41 (5), pp. 707-715. ISSN 0928-0987
Amani, A., York, P., Chrystyn, H. and Clark, B. (2010) ‘Evaluation of a nanoemulsion-based formulation for respiratory delivery of budesonide by nebulizers’ A A P S PharmSciTech , 11 (3), pp. 1147-1151. ISSN 1530-9932
Haughney, J., Price, D., Barnes, N., Virchow, J., Roche, N. and Chrystyn, H. (2010) ‘Choosing inhaler devices for people with asthma: Current knowledge and outstanding research needs ’ Respiratory Medicine , 104 (9), pp. 1237-1245. ISSN 0954-6111
Abdelrahim, M., Plant, P. and Chrystyn, H. (2010) ‘In-vitro characterisation of the nebulised dose during non-invasive ventilation’ Journal of Pharmacy and Pharmacology , 62 (8), pp. 966-972. ISSN 0022-3573
Jamieson, L., Scally, A. and Chrystyn, H. (2010) ‘A randomised comparison of practice pharmacist-managed hypertension providing level 3 medication review versus usual care in general practice.’ Journal of applied therapeutic research , 7 (3), pp. 77-86. ISSN 1029-2659
Doyle, S., Lloyd, A., Williams, A., Chrystyn, H., Moffat, M., Thomas, M. and Price, D. (2010) ‘What happens to patients who have their asthma device switched without their consent?’ Primary Care Respiratory Journal , 19 (2), pp. 131-139. ISSN 1471-4418
Nikander, K., Petherbridge, I., Scarberry, E., Von Hollen, D., Vivano, J. and Chrystyn, H. (2010) ‘Mandibular advancement achieved through a stepped mouthpiece design can change the size of the upper airways.’ Respiratory drug delivery , 3, pp. 747-752.
Alaboud, A., Assi, K. and Chrystyn, H. (2010) ‘In vitro characterization of the emitted dose from the foradil aerolizer to identify the influence of inhalation flow, inhilation volume and the number of inhalations per dose’ Respiratory drug delivery , 3, pp. 803-806.
Nadarassan, D., Assi, K. and Chrystyn, H. (2010) ‘Aerodynamic characteristics of a dry powder inhaler at low inhalation flows using a mixing inlet with an Andersen Cascade Impactor?’ European Journal of Pharmaceutical Sciences , 39 (5), pp. 348-354. ISSN 0928-0987
Bojke, C., Philips, Z., Hill, G., Hilton, A., Miles, J., Russell, I., Wong, I., Sculpher, M., Campion, P., Chrystyn, H., Coulton, S., Cross, B., Morton, V., Richmond, S. and Farrin, A. (2010) ‘Cost-effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings’ British Journal of General Practice , 60 (570), pp. 20-27. ISSN 0960-1643
Amani, A., York, P., Chrystyn, H. and Clark, B. (2010) ‘Factors Affecting the Stability of NanoemulsionsUse of Artificial Neural Networks’ Pharmaceutical Research , 27 (1), pp. 37-45. ISSN 0724-8741
Richmond, S., Morton, V., Coulton, S., Chrystyn, H., Campion, P., Cross, B., Wong, I., Russell, I., Philips, Z., Miles, J., Hilton, A., Hill, G. and Farrin, A. (2010) ‘Effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings’ British Journal of General Practice , 60 (570), pp. 10-19. ISSN 0960-1643
Chrystyn, H. and Price, D. (2009) ‘Not all asthma inhalers are the same: factors to consider when prescribing an inhaler’ Primary Care Respiratory Journal , 18 (4), pp. 243-249. ISSN 1471-4418
Amani, A., Chrystyn, H., Clark, B., Abdelrahim, M. and York, P. (2009) ‘Evaluation of supercritical fluid engineered budesonide powder for respiratory delivery using nebulisers’ Journal of Pharmacy and Pharmacology , 61 (12), pp. 1625-1630. ISSN 0022-3573
Mazhar, S. and Chrystyn, H. (2009) ‘New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation’ Journal of Pharmaceutical and Biomedical Analysis , 50 (2), pp. 175-182. ISSN 0731-7085
De Matas, M., Shao, Q., Biddiscombe, M., Chrystyn, H., Barnes, P. and Usmani, O. (2009) ‘In viro in vivo correlations for a short acting bronchodilator using artificial neural networks.’. In: RDD Europe 2009. : Davis Healthcare International. pp. 395-398. ISBN 1933722312
Chrystyn, H., Abdelmoby, M., Eagland, D., Nadarassan, D. and Britland, S. (2009) ‘Improved Pulmonary Delivery and Retention of a Budesonide Nanagel Clear Solution ’. In: RDD Europe 2009. : Davis Healthcare International. pp. 405-408. ISBN 1933722312
Chrystyn, H. and Price, D. (2009) ‘What you need to know about inhalers and how to use them’ Prescriber , 20 (12), pp. 47-52. ISSN 0959-6682
Abdelrahim, M. and Chrystyn, H. (2009) ‘Aerodynamic Characteristics of Nebulized Terbutaline Sulphate Using the Next Generation Impactor (NGI) and CEN Method ’ Journal of Aerosol Medicine and Pulmonary Drug Delivery , 22 (1), pp. 19-28. ISSN 1941-2703
Thomas, M., Chrystyn, H., Leyshon, J., Price, D., Roberts, J. and Russell, R. (2009) ‘Consensus guideline on the use of inhaler devices in asthma’ Guidelines , 39, pp. 100-104.
Chrystyn, H (2009) ‘Effects of device design on patient compliance : Comparing the same drug in different devices.’. In: RDD Europe 2009. : Davis Healthcare International. pp. 105-116. ISBN 1933722304
Thomas, M., Price, D., Chrystyn, H., Lloyd, A., Williams, A. and von Ziegenweidt, J. (2009) ‘Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control’ BMC Pulmonary Medicine , 9 (1), pp. 1-10. ISSN 1471-2466
Haughney, J., Price, D., Kaplan, A., Chrystyn, H., Horne, R., May, N., Moffat, M., Versnel, J., Shanahan, E. and Hillyer, E. (2008) ‘Achieving asthma control in practice: Understanding the reasons for poor control’ Respiratory Medicine , 102 (12), pp. 1681-1693. ISSN 0954-6111
Amani, A., York, P., Chrystyn, H., Clark, B. and Do, D. (2008) ‘Determination of factors controlling the particle size in nanoemulsions using Artificial Neural Networks’ European Journal of Pharmaceutical Sciences , 35 (1-2), pp. 42-51. ISSN 09280987
Mazhar, S., Ismail, N., Newton, D. and Chrystyn, H. (2008) ‘Relative lung deposition of salbutamol following inhalation from a spacer and a Sidestream jet nebulizer following an acute exacerbation’ British Journal of Pharmacology , 65 (3), pp. 334-337. ISSN 0306-5251
De Matas, M., Shao, Q., Richardson, C. and Chrystyn, H. (2008) ‘Evaluation of in vitro in vivo correlations for dry powder inhaler delivery using artificial neural networks’ European Journal of Pharmaceutical Sciences , 33 (1), pp. 80-90. ISSN 09280987
de Gatas, M., Shao, Q., Silkstone, D. and Chrystyn, H. (2007) ‘Evaluation of an in vitro in vivo correlation for nebulizer delivery using artificial neural networks’ Journal of Pharmaceutical Sciences , 96 (12), pp. 3293-3303. ISSN 0022-3549
Al-Showair, R., Tarsin, W., Assi, K., Pearson, S. and Chrystyn, H. (2007) ‘Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?’ Respiratory Medicine , 101 (11), pp. 2395-2401. ISSN 09546111
Richardson, C., De Matas, M., Hosker, H., Mukherjee, R., Wong, I. and Chrystyn, H. (2007) ‘Determination of the Relative Bioavailability of Salbutamol to the Lungs Following Inhalation from Dry Powder Inhaler Formulations Containing Drug Substance Manufactured by Supercritical Fluids and Micronization’ Pharmaceutical Research , 24 (11), pp. 2008-2017. ISSN 07248741
Williams, A. and Chrystyn, H. (2007) ‘Survey of pharmacists attitudes towards interchangeable use of dry powder inhalers’ Pharmacy World & Science , 29 (3), pp. 221-227. ISSN 09281231
Nadarassan, D., Chrystyn, H., Clark, B. and Assi, K. (2007) ‘Validation of high-performance liquid chromatography assay for quantification of formoterol in urine samples after inhalation using UV detection technique’ Journal of Chromatography B , 850 (1-2), pp. 31-37. ISSN 15700232
Chrystyn, H (2007) ‘The Diskus (TM): a review of its position among dry powder inhaler devices’ International Journal of Clinical Practice , 61 (6), pp. 1022-1036. ISSN 13685031
Al-Showair, R., Pearson, S. and Chrystyn, H. (2007) ‘The potential of a 2Tone trainer to help patients use their metered dose inhalers’ Chest , 131, pp. 1776-1782. ISSN 0012-3692
Chrystyn, H (2006) ‘Closer to an 'Ideal Inhaler' with the Easyhaler: an innovative dry powder inhaler’ Clinical Drug Investigation , 26 (4), pp. 175-183. ISSN 11732563
Theophilus, A., Moore, A., Prime, D., Rossomanno, S., Whitcher, B. and Chrystyn, H. (2006) ‘Co-deposition of salmeterol and fluticasone propionate by a combination inhaler’ International Journal of Pharmaceutics , 313, pp. 14-22. ISSN 0378-5173
Tarsin, W., Pearson, S., Assi, K. and Chrystyn, H. (2006) ‘Emitted dose estimates from Seretide, Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics’ International Journal of Pharmaceutics , 316, pp. 131-137. ISSN 0378-5173
Chrystyn, H., Elfituri, H., Sherif, F. and Elmahaishai, M. (2006) ‘18-month progestogen-only contraception during breast-feeding in Libyan women’ Pan Arab Medical Journal (5), pp. 28-32.
Assi, K., Tarsin, W. and Chrystyn, H. (2006) ‘High performance liquid chromatography assay method for simultaneous quantitation of formoterol and budesonide in Symbicort Turbuhaler’ Journal of Pharmaceutical and Biomedical Analysis , 41 (1), pp. 325-328. ISSN 07317085
Tomlinson, H., Corlett, S., Allen, M. and Chrystyn, H. (2005) ‘Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge’ British Journal of Clinical Pharmacology , 60 (6), pp. 605-610. ISSN 1365-2125
We have developed pharmacokinetic methods to determine the relative and total lung bioavailability of a variety of drugs. The work is now ready to be extended to inhaled steroids. State-of-the-art assay methods will be developed and used to measure steroid drug concentrations in samples collected after an inhalation of a corticosteroid. Pharmacokinetic studies will include healthy volunteers and patients
There are a variety of inhalers available for patients and each has its unique method of use. There is a lot of published literature that highlights the problems patients have using each inhaler. Methods to help patients maintain the recommended inhalation method will be designed and studies will be carried out to determine the effectiveness of the methods. Studies will use patients with asthma and chronic obstructive airways disease
Drugs are delivered to the lungs by inhalation using various different inhalers for the management of asthma and chronic obstructive airways disease. Although the current products available are very similar when used optimally there is a large difference in the amount delivered to the lungs. There is also a large difference in the variability of lung deposition. Investigations will be carried out to determine why the formulations deliver different amounts.
Studies will also be focussed on developing formulations of non-aqueous drugs for delivery by inhalation
Pharmaceutical care of patients has become an established service provided by pharmacists especially within secondary care. We have demonstrated the healthcare benefits of pharmacists providing pharmaceutical care / medicine management to patients with hypertension and type 2 diabetes. Studies will be carried out to extend the work to patients with other disease states.
We have developed sophisticated methodologies to investigate prescribing trends with a focus on drugs used in the management of Coronary Heart Disease. This has been extended to the provision of non-pharmacological strategies to help those with Coronary Heart Disease. Studies will be carried out to further develop these approaches and extend to primary prevention. Further studies will address other disease areas